{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T11:09:00Z","timestamp":1724756940519},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,8,15]]},"DOI":"10.2169\/internalmedicine.3934-19","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T22:05:55Z","timestamp":1597442755000},"page":"1963-1970","source":"Crossref","is-referenced-by-count":3,"title":["Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center"],"prefix":"10.2169","volume":"59","author":[{"given":"Chinatsu","family":"Takai","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"},{"name":"Division of Clinical Nephrology and Rheumatology Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"},{"name":"Department of Orthopaedic Surgery, Showa University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunho","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"},{"name":"Department of Orthopaedic Surgery, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asami","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Nakazono","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Murasawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 4: 1932-1939, 1999."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 56: 2129-2134, 2007.","DOI":"10.1002\/art.22718"},{"key":"3","unstructured":"3. Tanaka Y, Takeuchi T, Mimori T, et al.; RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69: 1286-1291, 2010."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48, 1995.","DOI":"10.1002\/art.1780380107"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 25: 659-662, 1949.","DOI":"10.1001\/jama.1949.02900430001001"},{"key":"6","unstructured":"6. Kurasawa T, Nagasawa H, Kishimoto M, Amano K, Takeuchi T, Kameda H. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial. Mod Rheumatol 24: 561-566, 2014."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 18: 460-464, 2008.","DOI":"10.3109\/s10165-008-0089-1"},{"key":"8","unstructured":"8. Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 73: 75-85, 2014."},{"key":"9","unstructured":"9. Hirata S, Li W, Defranoux N, Cavet G, et al. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: a retrospective observational study. Mod Rheumatol 25: 344-349, 2015."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, et al. Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. PLoS One 13: e0192425, 2018.","DOI":"10.1371\/journal.pone.0192425"},{"key":"11","unstructured":"11. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 64: 2824-2835, 2012."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Matsuno H, Okada M, Sakai Y, et al. The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis. Mod Rheumatol 26: 51-56, 2016.","DOI":"10.3109\/14397595.2015.1059984"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ito S, Kobayashi D, Hasegawa E, et al. An analysis of the biological disease-modifying antirheumatic drug-free condition of adalimumab-treated rheumatoid arthritis patients. Intern Med 58: 511-519, 2019.","DOI":"10.2169\/internalmedicine.1332-18"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Naniwa T, Iwagaitsu S, Kajiura M. Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor inhibitor due to clinical remission. Mod Rheumatol 27: 29-34, 2017.","DOI":"10.3109\/14397595.2016.1174394"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Hidaka T, Hashiba Y, Nishi E, Kai Y, Kuroda H, Maeda K. Effectiveness of infliximab dose escalation therapy in patients with rheumatoid arthritis in accordance with a protocol - Possibility of reduction or discontinuation of infliximab after dose escalation therapy in daily clinical practice -. Clinical Rheumatology and Related Research 28: 260-270, 2016 (in Japanese, Abstract in English).","DOI":"10.14961\/cra.28.260"},{"key":"16","unstructured":"16. Kobayashi D, Ito S, Takai C, et al. Efficacy and safety of infliximab: a comparison with other biological disease-modifying anti-rheumatic drugs. Mod Rheumatol 28: 599-605, 2018."},{"key":"17","unstructured":"17. Tanaka Y, Oba K, Koike T, et al. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Ann Rheum Dis 79: 94-102, 2020."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sato E, Tanaka E, Nakajima A, et al. Assessment of the effectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice. Mod Rheumatol 25: 528-533, 2015.","DOI":"10.3109\/14397595.2014.995892"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67: 189-194, 2008.","DOI":"10.1136\/ard.2007.072967"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_3934-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T03:10:54Z","timestamp":1597461054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_3934-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":19,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3934-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,15]]}}}